T1	p 81 130	children and adolescents with autistic disorder .
T2	p 282 332	children and adolescents with autistic disorders .
T3	p 392 395	OLE
T4	p 415 450	( 5-17 years of age , who completed
T5	p 539 550	risperidone
T6	p 634 641	20 to <
T7	p 685 689	? 45
T8	p 805 814	Fifty-six
T9	p 828 865	of 79 enrolled patients completed the
T10	p 1177 1204	respiratory tract infection
T11	p 2015 2037	autistic , psychiatric
T12	p 2040 2043	and
T13	p 2055 2066	disorders .
T14	i 66 77	risperidone
T15	i 220 231	risperidone
T16	i 380 395	extension ( OLE
T17	i 539 556	risperidone based
T18	i 724 735	risperidone
T19	i 1584 1595	risperidone
T20	i 1820 1864	risperidone treatment ( maximum weight-based
T21	i 1873 1892	1.25 mg/day or 1.75
T22	i 2000 2011	risperidone
T23	o 43 62	safety and efficacy
T24	o 187 203	long-term safety
T25	o 208 216	efficacy
T26	o 244 278	irritability and related behaviors
T27	o 565 573	weight .
T28	o 739 756	safety ; efficacy
T29	o 795 804	. RESULTS
T30	o 950 974	or adverse events ( AE )
T31	o 1046 1075	AEs were increased appetite (
T32	o 1093 1122	increased weight and vomiting
T33	o 1146 1204	sedation , pyrexia , and upper respiratory tract infection
T34	o 1228 1243	nasopharyngitis
T35	o 1262 1288	and somnolence and fatigue
T36	o 1312 1330	Extrapyramidal AEs
T37	o 1381 1392	mean weight
T38	o 1409 1424	body mass index
T39	o 1490 1498	increase
T40	o 1517 1564	prolactin-related AE ( irregular menstruation )
T41	o 1629 1676	mean improvement in sleep visual analog scale (
T42	o 1715 1751	improvement in efficacy scale scores
T43	o 1799 1805	safety
T44	o 1945 1947	DB
T45	o 2026 2039	psychiatric ,
T46	o 2104 2153	improvement in irritability and related behaviors